Supreme™ laryngeal mask airway insertion requires a lower concentration of sevoflurane than ProSeal™ laryngeal mask airway insertion during target-controlled remifentanil infusion: a prospective randomised controlled study

Table 4 Haemodynamic and BIS data at different times in the two groups

	PLMA (n = 23)	SLMA (n = 22)
Systolic arterial pressure
Baseline	138 ± 16	135 ± 20
Before insertion	98 ± 13 [29%]	96 ± 15 [29%]
1st min post-insertion*	101 ± 13 [27%]	108 ± 17 [20%]
6th min post-insertion*	98 ± 13 [29%]	97 ± 14 [28%]
Diastolic arterial pressure
Baseline	80 ± 12	79 ± 11
Before insertion*	56 ± 9 [30%]	53 ± 9 [33%]
1st min post-insertion*	58 ± 13 [30%]	60 ± 12 [24%]
6th min post-insertion*	55 ± 11 [31%]	57 ± 8 [28%]
Heart rate
Baseline	73 ± 17	73 ± 13
Before insertion*	56 ± 11 [23%]	54 ± 9 [26%]
1st min post-insertion*	57 ± 10 [22%]	59 ± 11 [19%]
6th min post-insertion*	56 ± 12 [23%]	60 ± 11 [18%]
BIS value
Baseline	95 ± 4	96 ± 5
Before insertion*†	60 ± 8 [37%]	63 ± 9 [35%]
1st min post-insertion*†	56 ± 13 [41%]	64 ± 14 [34%]
6th min post-insertion*†	41 ± 15 [57%]	43 ± 16 [55%]

Data are expressed as mean ± SD [% difference from baseline].
PLMA Laryngeal mask airway ProSeal™, SLMA Laryngeal mask airway Supreme™, BIS Bispectral index, SD Standard deviation.
* p < 0.05 for significant differences from baseline (difference within the group) by repeated measures ANOVA
† p < 0.05 for significant differences between the PLMA and the SLMA groups by repeated measures ANOVA.

ISSN: 1471-2253